Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL INTENSOL versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL INTENSOL versus THORAZINE.
HALOPERIDOL INTENSOL vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also has moderate affinity for alpha-1 adrenergic receptors and low affinity for H1 histamine and muscarinic cholinergic receptors.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
Oral (Intensol): 0.5-5 mg twice or three times daily. Maximum: 100 mg/day.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 14-37 hours (average 21 hours) after oral administration; may be longer in elderly or hepatic impairment.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Primarily hepatic metabolism with renal elimination of metabolites; about 40% excreted in urine and 15% in feces via bile.
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic